Table 3 Clinical and laboratory outcome measures of the studied patients’ groups

Time elapsed for resolution of failure symptoms^b (h)

56 ± 18.5

42.1 ± 9.0

0.001

Furosemide dose in the first 2 days^b (mg/kg/day)

4.7 ± 1.0

3.5 ± 0.6

0.001

Serum sodium at the end of furosemide injection^b (mmol/l)

141.8 ± 1.5

142.4 ± 2.5

0.289

Serum potassium at the end of furosemide injection^b (mmol/l)

3.1 ± 0.2

3.1 ± 0.4

0.890

Serum creatinine at the end of furosemide injection^b (mg/dl)

0.34 ± 0.1

0.39 ± 0.06

0.030

Serum creatinine at hospital discharge^b (mg/dl)

0.33 ± 0.06

0.32 ± 0.05

0.584

Length of hospital stay^b (days)

12.2 ± 3.0

12.4 ± 3.2

0.724

30 days rehospitalization rate for ADHF^a

9 (33.3%)

7 (25.9%)

0.766

In-hospital mortality^a

0

0

30 days mortality^a

0

0